Abstract
Berberine is an alkaloid found in plants. It has neuroprotective, anti-inflammatory and hypolipidemic activities. The research proves that it also strongly impacts carbohydrate metabolism. The compound also protects pancreatic β-cells and increases sensitivity to insulin in peripheral tissues via the induction of GLUT-1, GLUT-4 and insulin type 1 (Ins-1) receptors activity. It also stimulates glycolysis and leads to a decrease in insulin resistance by macrophages polarization, lipolytic processes induction and energy expenditure enhancement (by reducing body mass and limiting insulin resistance caused by obesity). In liver berberine inhibits FOX01, SREBP1 and ChREBP pathways, and HNF-4α (hepatocyte nuclear factor 4 alpha) mRNA that hinder gluconeogenesis processes. In the intestines it blocks α-glucosidase contributing to glucose absorption decrease. Its interference in intestinal flora reduces levels of monosaccharides and suppresses diabetes mellitus complications development.
Keywords: Berberine, alkaloid, diabetes mellitus, metabolism, nutrition, review.
Graphical Abstract
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:Berberine in the Treatment of Diabetes Mellitus: A Review
Volume: 21 Issue: 8
Author(s): Aleksandra Baska*, Kamil Leis and Przemysław Gałązka
Affiliation:
- Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, ul. Jagiellonska 13/15, 85-090Bydgoszcz,Poland
Keywords: Berberine, alkaloid, diabetes mellitus, metabolism, nutrition, review.
Abstract: Berberine is an alkaloid found in plants. It has neuroprotective, anti-inflammatory and hypolipidemic activities. The research proves that it also strongly impacts carbohydrate metabolism. The compound also protects pancreatic β-cells and increases sensitivity to insulin in peripheral tissues via the induction of GLUT-1, GLUT-4 and insulin type 1 (Ins-1) receptors activity. It also stimulates glycolysis and leads to a decrease in insulin resistance by macrophages polarization, lipolytic processes induction and energy expenditure enhancement (by reducing body mass and limiting insulin resistance caused by obesity). In liver berberine inhibits FOX01, SREBP1 and ChREBP pathways, and HNF-4α (hepatocyte nuclear factor 4 alpha) mRNA that hinder gluconeogenesis processes. In the intestines it blocks α-glucosidase contributing to glucose absorption decrease. Its interference in intestinal flora reduces levels of monosaccharides and suppresses diabetes mellitus complications development.
Export Options
About this article
Cite this article as:
Baska Aleksandra*, Leis Kamil and Gałązka Przemysław , Berberine in the Treatment of Diabetes Mellitus: A Review, Endocrine, Metabolic & Immune Disorders - Drug Targets 2021; 21 (8) . https://dx.doi.org/10.2174/1568026620666201022144405
DOI https://dx.doi.org/10.2174/1568026620666201022144405 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Adverse Effects of Smoking on Health Outcomes in Bipolar Disorder: A Review and Synthesis of Biological Mechanisms
Current Molecular Medicine Increased Alzheimer’s Disease Neuropathology is Associated with Type 2 Diabetes and ApoE ε4 Carrier Status
Current Alzheimer Research Pharmacological Treatment of Obesity, Food Intake, and Reversal of Metabolic Disorders
Current Nutrition & Food Science Hypothyroidism and Nephrotic Syndrome: Why, When and How to Treat
Current Vascular Pharmacology Amniotic Fluid Stem Cells: a Promising Therapeutic Resource for Cell-Based Regenerative Therapy
Current Pharmaceutical Design Patent Selections:
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Recent Advancements in Diagnosis and Therapy of Liver Cirrhosis
Current Drug Targets Role of PPAR-γ Agonist Thiazolidinediones in Treatment of Pre-Diabetic and Diabetic Individuals: A Cardiovascular Perspective
Current Drug Targets - Cardiovascular & Hematological Disorders Biological Abilities of Rice Bran-Derived Antioxidant Phytochemicals for Medical Therapy
Current Topics in Medicinal Chemistry Novel Inflammatory Markers in Hyperlipidemia: Clinical Implications
Current Medicinal Chemistry Niemann-Pick C1-Like 1 (NPC1L1) Inhibition and Cardiovascular Diseases
Current Medicinal Chemistry Expansion of Umbilical Cord Blood for Clinical Transplantation
Current Stem Cell Research & Therapy Scientific and Clinical Challenges in Sepsis
Current Pharmaceutical Design Patent Selections
Recent Patents on Food, Nutrition & Agriculture Metabolic Targeting of Cancers: From Molecular Mechanisms to Therapeutic Strategies
Current Medicinal Chemistry Insulin Attenuates Diabetes-Related Mitochondrial Alterations: A Comparative Study
Medicinal Chemistry The Effects of Direct Renin Inhibitor, Aliskiren, on Arterial Hypertension, Chronic Kidney Disease and Cardiovascular Disease: Optimal Pharmacotherapy
Cardiovascular & Hematological Agents in Medicinal Chemistry Derivatives of 6-Nitrobenzimidazole Inhibit Fructose-Mediated Protein Glycation and Intracellular Reactive Oxygen Species Production
Medicinal Chemistry Subject Index to Volume 3
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Ex Vivo Gene Transfer for Improvement of Transplanted Pancreatic Islet Viability and Function
Current Pharmaceutical Design